ReviewInsights into imaging2019
Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review.
Review in Insights into imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Liver Segment and Lesion Segmentation on CT and MRI: An Open-Source Contribution to TotalSegmentator.Journal of imaging informatics in medicine · 2026Article
- Review
- The 2024 LI-RADS treatment response update: practical reporting after non-radiation and radiation locoregional therapies for hepatocellular carcinoma.Insights into imaging · 2026Review
- Evaluation of the LI-RADS radiation treatment response assessment v2024 in comparison with the modified RECIST.European radiology · 2025Article
- Explainable artificial intelligence and ensemble learning for hepatocellular carcinoma classification: State of the art, performance, and clinical implications.World journal of hepatology · 2025Review
- Article
- LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features.Abdominal radiology (New York) · 2024Article
- Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI.Journal of magnetic resonance imaging : JMRI · 2023Review
- Article
- Repeated trans-arterial treatments of LDL-DHA nanoparticles induce multiple pathways of tumor cell death in hepatocellular carcinoma bearing rats.Frontiers in oncology · 2022Article
- Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort study.Journal of cancer research and clinical oncology · 2021Article
- LI-RADS treatment response lexicon: review, refresh and resolve with emerging data.Abdominal radiology (New York) · 2021Review
- LI-RADS treatment response assessment of combination locoregional therapy for HCC.Abdominal radiology (New York) · 2021Review
- Colorectal Cancer, Liver Metastases and Biotherapies.Biomedicines · 2021Review
- Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2021Review
- Article
- Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions.World journal of hepatology · 2020Review
- Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response.Abdominal radiology (New York) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Computed tomography (CT) and magnetic resonance imaging (MRI) play critical roles for assessing treatment response of hepatocellular carcinoma (HCC) after locoregional therapy. Interpretation is challenging because posttreatment imaging findings depend on the type of treatment, magnitude of treatment response, time interval after treatment, and other factors. To help radiologists interpret and report treatment response in a clear, simple, and standardized manner, the Liver Imaging Reporting and Data System (LI-RADS) has developed a Treatment Response (LR-TR) algorithm. Introduced in 2017, the system provides criteria to categorize response of HCC to locoregional treatment (e.g., chemical ablation, energy-based ablation, transcatheter therapy, and radiation therapy). LR-TR categories include Nonevaluable, Nonviable, Equivocal, and Viable. LR-TR does not apply to patients on systemic therapies. This article reviews the LR-TR algorithm; discusses locoregional therapies for HCC, treatment concepts, and expected posttreatment findings; and illustrates LI-RADS treatment response assessment with CT and MRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.